Regensburg 2010 – wissenschaftliches Programm
Bereiche | Tage | Auswahl | Suche | Downloads | Hilfe
ST: Fachverband Strahlen- und Medizinphysik
ST 12: High-LET Radiation Therapy 2
ST 12.1: Vortrag
Donnerstag, 25. März 2010, 11:00–11:20, H41
Three Dimensional Biological Dose Distribution of Antiprotons — •Sara Tegami1, Rebecca Boll1, Stefan Sellner1, Carsten P. Welsch1,2, and Michael H. Holzscheiter1,3 — 1Max-Planck-Institut für Kernphysik, Heidelberg, Deutschland — 2Cockcroft Institute and University of Liverpool, UK — 3University of New Mexico, Albuquerque, USA
The goal of external beam cancer therapy is to destroy the tumour while sparing the healthy tissue around it. In hadron therapy, the dose profile of heavy charged particles satisfies this request, because most of the energy is deposited at the end of the particle path, in the Bragg peak. Antiprotons are even more promising, thanks to the extra energy released by annihilation when captured in a normal atom at the end of range.
The aim of the AD-4/ACE experiment at CERN is to determine the increase in biological dose near the Bragg peak due to densely ionizing particles emanating from the annihilation of antiprotons. Initial experiments showed the damage to cells inflicted at the end of the beam for identical damage at the skin level to be four times higher for antiprotons than for protons. The radiation field in a spread-out Bragg peak produced with antiprotons is highly mixed and for proper dose planning knowledge of linear energy transfer (LET) and relative biological efficiency (RBE) at any point in the target is needed.
We are studying a number of detection methods for their response to mixed radiation fields with the goal to obtain a direct measurement of the 3D LET distribution and will report on first results.